Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6627580 | 0.82 | ALDH1A1 (0.40) | L3MBTL1ALDH1A1GLAHTTKDM4E | |
| SCHEMBL4068543 | 0.79 | L3MBTL1 (0.33) | L3MBTL1ALDH1A1GLAHTTKDM4E | |
| SCHEMBL11723001 | 0.78 | HTT (0.42) | L3MBTL1ALDH1A1GLAHTTKDM4E | |
| SCHEMBL1624060 | 0.78 | L3MBTL1 (0.33) | L3MBTL1ALDH1A1GLAHTT | |
| SCHEMBL27348192 | 0.75 | KHK (0.36) | L3MBTL1ALDH1A1GLAHTTKDM4E | |
| SCHEMBL25302521 | 0.74 | FFAR1 (0.43) | ALDH1A1HPGD | |
| SCHEMBL22980966 | 0.72 | KHK (0.34) | L3MBTL1ALDH1A1GLAHTTKDM4E | |
| SCHEMBL4193505 | 0.72 | HTT (0.38) | L3MBTL1ALDH1A1GLAHTTKDM4E | |
| SCHEMBL9987538 | 0.71 | L3MBTL1 (0.33) | L3MBTL1ALDH1A1GLAHTTHPGD | |
| SCHEMBL4064564 | 0.69 | ALDH1A1 (0.40) | L3MBTL1ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209558-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | CUREGENIX, INC. (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209558-A1 | COMPOUNDS FOR TREATMENT OF FIBROSIS DISEASES | WNT1, SFRP1, WNT3 | TAAR1 3826/4885HRH3 1283/4885L3MBTL1 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.